抗 CD19 CAR-T 疗法治疗高剂量甲氨蝶呤难治性继发性中枢神经系统淋巴瘤的安全性与有效性研究

《Blood Immunology & Cellular Therapy》：EFFICACY AND SAFETY OF ANTI-CD19 CAR T-CELL THERAPY IN SECONDARY CNS LYMPHOMAS REFRACTORY TO HIGH-DOSE METHOTREXATE-BASED TREATMENT

　　- 抗CD19 CAR-T疗法对于对高剂量甲氨蝶呤为基础的治疗难治的继发性中枢神经系统淋巴瘤是一种安全有效的治疗方案- 根据个体化多模态维持治疗的反应来筛选适合CAR-T的患者，其ICANS发生率较低，两年生存率为68%Piera Angelillo | Edoardo Campodonico | Teresa Calimeri | Alice Di Rocco | Alessia Castellino | Andrea Assanelli | Lorenzo Lazzari | Maria Teresa Lupo-Stanghellini | Maddalena Noviello | Livia Donzelli | Claudia Castellino | Andrea Ferrario | Melania Celli | Astrid Pavlovsky | Nicoletta Anzalone | Paolo Vezzulli | Federico Fallanca | Anna Chiara | Francesco Ancona | Laura Falcone | Andres J. M. Ferreri